{"id":3906,"count":60,"description":"Mental health and psychiatric conditions \u2014 major depression, generalised anxiety, panic disorder, OCD, PTSD, social anxiety, bipolar disorder, schizophrenia, ADHD, OCD, and chronic insomnia \u2014 affect roughly one in four adults globally over the course of a lifetime. Modern psychopharmacology is built around eight main drug families, each suited to particular diagnoses and patient profiles. The MedsBase Mental Health & Psychiatric Medications catalogue carries 57 products<\/strong> across all of these classes, supplied by WHO-GMP \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2<\/strong>.\n\nSSRIs (selective serotonin reuptake inhibitors)<\/strong> are the most prescribed first-line option for major depressive disorder, generalised anxiety, panic disorder, OCD, and PTSD. We stock sertraline as Sertafine<\/a> generics already covered in our Antidepressants line, paroxetine as Xet 20<\/a> \u03ba\u03b1\u03b9 Pexep<\/a> \/ Pexep CR<\/a> (controlled-release for less morning sedation), escitalopram as Lexaheal<\/a>, citalopram as Citapad<\/a>, fluoxetine as Flunil<\/a>, fluvoxamine as Ocivox<\/a> (preferred for OCD), and vilazodone \u2014 a partial 5-HT1A agonist with reduced sexual side-effects.\n\nSNRIs (serotonin\u2013noradrenaline reuptake inhibitors)<\/strong> add noradrenergic action and are useful in MDD with prominent fatigue or pain, GAD, fibromyalgia, and diabetic neuropathic pain. We carry venlafaxine as \u0391\u03c6\u03c6\u03b5\u03be\u03cc\u03c1 XR<\/a>, Venish SR<\/a>, Venpad XR<\/a>, \u03ba\u03b1\u03b9 Ventab XL<\/a> (extended-release reduces nausea), duloxetine as Dulata<\/a> \u03ba\u03b1\u03b9 Duvanta<\/a>, and atomoxetine as \u0391\u03c4\u03bf\u03bc\u03bf\u03be\u03b5\u03c4<\/a> (selective NRI, used for ADHD).\n\nTricyclic and tetracyclic antidepressants<\/strong> remain valuable second-line options where SSRIs\/SNRIs have failed, and for specific indications such as nocturnal enuresis, neuropathic pain, and migraine prophylaxis. Imipramine is available as D-mine<\/a>, opipramol (an atypical TCA-related sigma-receptor agonist used for GAD and somatoform disorders) as Opiprol<\/a>, and the tetracyclic NaSSA mirtazapine as Nasdep<\/a>, Mirtaz<\/a>, Mirzacan<\/a>, Mirnite<\/a> \u2014 useful when both depression and insomnia coexist (paradoxically more sedating at 15 mg than at 30+ mg).\n\nAtypical antidepressants<\/strong> include trazodone (a SARI most often prescribed off-label as a low-dose hypnotic) as Trazalon<\/a>, Trazonil<\/a>, \u03ba\u03b1\u03b9 Tridon<\/a>; bupropion (NDRI, no sexual side-effects, weight-neutral, also FDA-approved for smoking cessation) as Bupron XL<\/a>, Bulet SR<\/a>, \u03ba\u03b1\u03b9 Bupcart-XL 150<\/a>; agomelatine (melatonin agonist + 5-HT2C antagonist) as \u0391\u03b3\u03ba\u03bf\u03c0\u03c1\u03ad\u03be<\/a>; and dosulepin \/ dothiepin generics in the Depsol<\/a> line.\n\nAnxiolytics and anxiety adjuncts.<\/strong> Buspirone (5-HT1A partial agonist, non-sedating, non-dependence-forming) is available as Busiron<\/a>; hydroxyzine (H1 antihistamine with anxiolytic effect, useful for situational anxiety) as Atarax<\/a> \u03ba\u03b1\u03b9 Atarise<\/a>. The classical anxiety adjuncts, propranolol and benzodiazepines, are listed under Heart & Blood Pressure and Sleeping Tablets respectively.\n\nAtypical (second-generation) antipsychotics<\/strong> are the modern mainstays for schizophrenia, schizoaffective disorder, and bipolar disorder, with selected agents also used as augmentation in treatment-resistant depression. We carry olanzapine as Olanzap<\/a>, Oliza<\/a>, Olanzoop<\/a>, Olimelt<\/a> (orodispersible), and Onlee-10<\/a>; risperidone as Risdone<\/a> \u03ba\u03b1\u03b9 Risdone MT<\/a> (mouth-dispersible); paliperidone (the active metabolite of risperidone) as Palip XR<\/a>; quetiapine as Seroquit<\/a> (IR) and Qutan SR 400<\/a> (XR); aripiprazole as Aripicon<\/a>, Arizole<\/a>, \u03ba\u03b1\u03b9 Arzodel<\/a>; ziprasidone (with mandatory food rule + QT monitoring); and lurasidone as Lurasid<\/a>, Lurakem<\/a>, Lurafic<\/a>, \u03ba\u03b1\u03b9 Atlura<\/a> (low metabolic burden \u2014 preferred when weight gain or dyslipidaemia are concerns).\n\nFirst-generation (typical) antipsychotics<\/strong> remain in use for selected indications. Thioridazine is available as Thioril<\/a>, sulpiride as Sulpitac<\/a>, and the trifluoperazine + trihexyphenidyl combination as Trinicalm Plus (listed under Anxiety \/ Psychiatric medications). Modern practice prefers atypical monotherapy where feasible because of lower extrapyramidal and tardive-dyskinesia burden.\n\nMood stabilisers<\/strong> for bipolar disorder include lithium as Lithosun<\/a>, Monolith<\/a>, Licab<\/a>, \u03ba\u03b1\u03b9 Licab XL<\/a> (extended-release reduces tremor and GI upset), and divalproex \/ sodium valproate as Valprol-CR<\/a>, Torvate<\/a>, \u03ba\u03b1\u03b9 Tritin<\/a>. Lithium remains first-line for classical bipolar I and reduces suicidality on long-term use; valproate is the alternative when rapid cycling or mixed states predominate.\n\nAnti-OCD and obsessional-spectrum agents.<\/strong> Clomipramine (the most serotonergic TCA) is available as Obsenil<\/a> for OCD when SSRIs alone have failed.\n\nOther agents and adjuncts.<\/strong> Pimozide is available as Mozep<\/a> (selected use in delusional disorder + Tourette's). Dosulepin (TCA) for elderly depression sits in the Antidep<\/a> line. Memantine generics for moderate-to-severe Alzheimer's-related agitation are stocked in the Alzheimer's Treatment category. Specialty agents include flibanserin (FDA-approved for premenopausal HSDD) as Fliban<\/a>, ashwagandha (an evidence-supported adaptogen for stress and mild anxiety) as Ashvagandha<\/a>, the doxepin-line atypical TCA as Doxin<\/a> \u03ba\u03b1\u03b9 Spectra<\/a>, and clozapine analogue brands such as Skizoril<\/a> for treatment-resistant schizophrenia.\n\n\u03a0\u03ce\u03c2 \u03bd\u03b1 \u03b5\u03c0\u03b9\u03bb\u03ad\u03be\u03b5\u03c4\u03b5.<\/strong> SSRIs are first-line for most anxiety and depression in primary care; switch to SNRIs if pain or fatigue dominates, to mirtazapine if sleep and appetite are problems, to bupropion if weight gain or sexual side-effects are a concern, and to atypical antipsychotic augmentation (low-dose aripiprazole or quetiapine) for partial response. For bipolar disorder, lithium and valproate remain mainstays with atypical antipsychotics for acute mania or mixed states. Schizophrenia and schizoaffective disorder are best initiated on atypicals (olanzapine, risperidone, aripiprazole, lurasidone) under specialist supervision. Never stop antidepressants or mood stabilisers abruptly<\/strong> \u2014 taper over 2\u20134 weeks minimum, longer for paroxetine and venlafaxine (worst discontinuation syndromes of their classes). For acute crisis (suicidality, psychotic emergency), call your local emergency number rather than self-medicating.\n\nAll MedsBase Mental Health & Psychiatric Medications ship from WHO-GMP \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2<\/strong> with discreet packaging, are covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>, and qualify for our customer loyalty programme.\n\n2026 buyer's guide:<\/strong> \u0394\u03b5\u03af\u03c4\u03b5 \u03c4\u03b7\u03bd shortlist \u03bc\u03b1\u03c2 Best Antidepressants 2026<\/a> \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c4\u03b1\u03c4\u03ac\u03be\u03b5\u03b9\u03c2, \u03c0\u03af\u03bd\u03b1\u03ba\u03b1 \u03c3\u03c5\u03b3\u03ba\u03c1\u03af\u03c3\u03b5\u03c9\u03bd, \u03c3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03c3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03ad\u03c2 \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae\u03c2.","link":"https:\/\/medsbase.com\/el\/mental-health-and-psychiatric-medications\/","name":"\u03a8\u03c5\u03c7\u03b9\u03ba\u03ae \u03a5\u03b3\u03b5\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a8\u03c5\u03c7\u03bf\u03c4\u03c1\u03cc\u03c0\u03b1 \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1","slug":"mental-health-and-psychiatric-medications","taxonomy":"product_cat","parent":3342,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat\/3906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat\/3342"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product?product_cat=3906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}